Forbes Innovation Healthcare Under New CEO Wentworth, Walgreens Continues To Sell Off Distributor Stake Bruce Japsen Senior Contributor Opinions expressed by Forbes Contributors are their own. I write about healthcare business and policy Following Click to save this article. You'll be asked to sign into your Forbes account. Nov 10, 2023, 11:41pm EST Press play to listen to this article! Got it! Share to
Facebook Share to
Twitter Share to Linkedin Walgreens Boots Alliance has sold shares of drug distributor Cencora, formerly AmerisourceBergen, ... [+] for proceeds of $674 million, which will be used “debt paydown and general corporate purposes,” the company announced November 10, 2023. Walgreens and Walgreen Co. signage is shown outside their corporate offices in Deerfield, Illinois. (Photo by Tim Boyle/Getty Images) Getty Images Walgreens Boots Alliance has sold more shares of drug distributor Cencora, formerly AmerisourceBergen , for proceeds of $674 million, which will be used for “debt paydown and general corporate purposes.” The stock sale, which comes less than a month after former Express Scripts top executive Tim Wentworth became chief executive officer of Walgreens , brings the drugstore chain’s stake in Cencora down to 15% though Walgreens remains the drug distributor’s largest shareholder. “The transaction is another decisive action to further simplify the company’s portfolio, while improving cash management,” Walgreens said Friday in a statement. Walgreens began reducing its stake in the distributor and other businesses in the last two years under former chief executive Roz Brewer to raise money for other priorities such as its multi-billion dollar bet on doctor-staffed primary care clinics attached to drugstores. In May, Walgreens sold shares of Cencora, then known as AmerisourceBergen, for proceeds of $694 million. That transaction followed another sale of the distributor’s stock last December for proceeds of $1 billion, reducing its stake in the company to less than 20%. MORE FOR YOU Wegovy Maker Novo Nordisk Pumps $6 Billion To Boost Production As Obesity Drug Rival Zepbound Is Approved Counterfeit Ozempic Wegovy Mounjaro Pens Reported To FDA How To Spot A Fake Eyedrop Recall Casts Light On Lack Of Testing For U S Drugs The divestiture strategy continues under Wentworth even as he builds his new executive team. Walgreens earlier this month named Neal Sample as its new Executive Vice President and Chief Information Officer even as the company this week continued to pare its headcount at company headquarters, eliminating more than 260 corporate jobs. Sample’s experience includes stints as chief information officer at Northwestern Mutual and Express Scripts where he was chief operating officer and CIO when Wentworth was the pharmacy benefit manager’s CEO. Wentworth and Sample led Express Scripts through its $54 billion acquisition by health insurance giant Cigna in 2018. Walgreens has been spending billions of dollars to expand its primary care business and has used a mix of equity and debt to do so. Most notably, Walgreens has invested in VillageMD, which last year announced plans to buy Summit Health for $8.9 billion to expand doctor-staffed clinics across the country. That transaction included investments from Walgreens, which already owns about half of VillageMD, and Cigna’s health services business Evernorth. Walgreens and rivals CVS Health, Walmart and
Amazon are pushing deeper into providing medical care in drugstores and other retail settings. Follow me on Twitter or LinkedIn . Check out my website or some of my other work here . Bruce Japsen Editorial Standards Print Reprints & Permissions